P100018/S055: Pipeline Flex Embolization Device (Pipeline Flex); Pipeline Flex Embolization Device with Shield Technology (Pipelin
FDA’s recorded scope: a change to in-process monitoring for the Pipeline Flex Embolization Device
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 5 FDA records to the applicant name Micro Therapeutics, Inc. d/b/a ev3 Neurovascular. 2 entries are PMA supplements. 3 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Aug 14, 2025 to Jul 21, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code OUT appears in 5 of the 5 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P100018, with 5 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 9775 Toledo Way, Irvine, CA, 92618. Recorded on P100018/S055, decision dated Jul 21, 2026.
FDA’s recorded scope: a change to in-process monitoring for the Pipeline Flex Embolization Device
FDA’s recorded scope: approval to remove the X-ray Photelectron Spectroscopy (XPS) testing and its associated Statistical Process Control (SPC) recording for the application of Shield Technology to the Pipeline braid and additional enhanced process controls, including minimum fill height verification and the addition of a 9 mm guard band
FDA’s recorded scope: approval for the relocation of the Pipeline Flex and Pipeline Shield heat treatment and passivation operations from an ISO 8 Controlled Environment Area (CEA) to a Non-Controlled Area (Non-CEA) and the repositioning of the Pipeline implant braider within the Non-CEA
FDA’s recorded scope: Approval of claims regarding reduced material thrombogenicity of a proprietary surface modification for the Pipeline Flex Embolization Device with Shield Technology and Pipeline Vantage Embolization Device with Shield Technology supported by acute benchtop in-vitro testing.
FDA’s recorded scope: Approval for changes to the post-approval study (PAS) protocol for Pipeline Vantage device following the removal of the Vantage 027 devices, including updates to include additional follow-up imaging to assess for braid deformation events.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.